KalVista Pharmaceuticals (KALV) is back in focus after releasing interim KONFIDENT-KID data on EKTERLY, its oral hereditary angioedema treatment for children, showing effective on demand use and a favorable tolerability profile.

The KONFIDENT-KID update lands after a busy stretch for KalVista, with earnings in late March showing an eight month net loss of US$109.52 million and the share price now at US$19.77. This is supported by a 30 day share price return of 23.10% and a 1 year total shareholder return of 78.27%, which points to momentum building over the past year despite earlier volatility.

If this kind of clinical trial driven move has your attention, it could be a good moment to see what else is setting up in healthcare and biotech through our 33 healthcare AI stocks

With shares up 78.27% over the past year and trading at US$19.77 against an average analyst price target of US$34.33, the key question is whether KalVista is still mispriced or if the market is already factoring in potential future growth.

Most Popular Narrative: 36.2% Undervalued

KalVista's most followed narrative places fair value at $31.00 per share, compared with the latest close at $19.77. This sets up a valuation gap that hinges on EKTERLY's rollout and long term earnings potential.

International rollout, including launches in the U.S. and Germany and approvals in the U.K., EU, Switzerland and Australia, together with planned launches in the U.K. and Japan in 2026, broadens the addressable market. This can influence total revenue and help spread fixed operating costs over a larger sales base.

Want to see what kind of revenue curve and margin lift would need to follow that global footprint? The narrative leans on aggressive top line compounding, improving profitability and a premium earnings multiple to reach its fair value line.

Result: Fair Value of $31.00 (UNDERVALUED)

However, that upside view still depends on EKTERLY usage holding up as the patient mix broadens and on payers not tightening access or reimbursement terms over time.

Another View: Rich Sales Multiple Despite DCF Upside

Alongside the SWS DCF model, which points to a fair value of $88.04 and flags KalVista as trading at a 77.5% discount, the current P/S ratio of 13.8x tells a different story. It sits above the US Biotechs industry at 10.6x, the peer average at 9.1x and a fair ratio of 4.2x, which implies meaningful valuation risk if the market shifts closer to that fair ratio.

For a closer look at how this sales based view stacks up against cash flow estimates, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals or early stage inflection; either way, the market is clearly paying attention, so it makes sense to review the full picture of risks and upsides on your own terms and see the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If KalVista has sharpened your interest, now is the moment to broaden your watchlist with other focused stock ideas before the next wave of moves happens.

• Target quality at a discount by scanning 63 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your portfolio foundation by checking the solid balance sheet and fundamentals stocks screener (39 results) for companies that keep leverage and liquidity in tighter control.
• Get ahead of the crowd by reviewing the screener containing 25 high quality undiscovered gems before they attract wider attention and heavier trading interest.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.